Liminatus Pharma Statistics
Total Valuation
LIMN has a market cap or net worth of $7.85 million. The enterprise value is $8.96 million.
Important Dates
The next estimated earnings date is Friday, May 1, 2026.
| Earnings Date | May 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LIMN has 44.88 million shares outstanding. The number of shares has increased by 181.69% in one year.
| Current Share Class | 44.88M |
| Shares Outstanding | 44.88M |
| Shares Change (YoY) | +181.69% |
| Shares Change (QoQ) | +15.91% |
| Owned by Insiders (%) | 20.30% |
| Owned by Institutions (%) | 0.74% |
| Float | 29.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -62.65% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 30.33% |
| Weighted Average Cost of Capital (WACC) | 8.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.06% in the last 52 weeks. The beta is 0.63, so LIMN's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -98.06% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 2.64 |
| Relative Strength Index (RSI) | 35.07 |
| Average Volume (20 Days) | 1,432,266 |
Short Selling Information
The latest short interest is 995,395, so 2.22% of the outstanding shares have been sold short.
| Short Interest | 995,395 |
| Short Previous Month | 1.31M |
| Short % of Shares Out | 2.22% |
| Short % of Float | 3.42% |
| Short Ratio (days to cover) | 0.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.97M |
| Pretax Income | -10.21M |
| Net Income | -10.21M |
| EBITDA | -2.97M |
| EBIT | -2.97M |
| Earnings Per Share (EPS) | -$0.43 |
Full Income StatementBalance Sheet
The company has $337,655 in cash and $1.44 million in debt, with a net cash position of -$1.10 million or -$0.02 per share.
| Cash & Cash Equivalents | 337,655 |
| Total Debt | 1.44M |
| Net Cash | -1.10M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | -9.81M |
| Book Value Per Share | -0.36 |
| Working Capital | -9.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.96 million and capital expenditures -$13,108, giving a free cash flow of -$9.73 million.
| Operating Cash Flow | -9.96M |
| Capital Expenditures | -13,108 |
| Depreciation & Amortization | 1,285 |
| Net Borrowing | 3.74M |
| Free Cash Flow | -9.73M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
